ACTIV-2d, a global phase 3 trial of novel investigational COVID-19 oral antiviral agent, launches
Those suffering from autoimmune diseases require a third coronavirus vaccination
22 August 2022Modified bladder cancer treatment shows promise in animal studies
22 August 2022ACTIV-2d, a global phase 3 trial of novel investigational COVID-19 oral antiviral agent, launches
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which expanded its focus to conduct research into COVID-19, today announced the initiation of ACTIV-2d, a global, phase 3, multicenter trial to evaluate the impact of S-217622, an investigational oral COVID-19 antiviral agent. ACTIV-2d will evaluate the safety and efficacy of S-217622 as a once-daily treatment to reduce the duration of COVID-19 symptoms in non-hospitalized adults with early COVID-19.
